TNF and systemic sclerosis: This concludes our review of NLRP3 inflammasome signaling and associated cytokines of TNFα, IL-1β, and IL-18 as novel therapeutic targets in SSc-ILD; these findings are summarized in Table 1 and depicted in Figure 1.